March 31 (Reuters) - Syndax Pharmaceuticals Inc :
* SYNDAX ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO AXATILIMAB FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* SYNDAX ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO AXATILIMAB FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)